Skip to main content

GW Pharma stock rallies in declining cannabis sector after strong Epidiolex launch

GW Pharmaceuticals PLC shares were a standout among cannabis stocks Wednesday, after the company reported a strong start for Epidiolex, the first cannabis-based drug to win regulatory approval as a treatment for a severe form of childhood epilepsy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.